On Wednesday, AC Immune SA stock identified change of 196.92% away from 52-week low price and recently located move of -16.45% off 52-week high price. ACIU stock has been recorded 17.95% away from 50 day moving average and 61.80% away from 200 day moving average. Moving closer, we can see that shares have been trading 7.35% off 20-day moving average.
AC Immune SA (ACIU) recently provided a business and clinical update and stated its consolidated financial results for the third quarter of 2019.
Analysis of Financial Statements for the Three and Nine Months Ended September 30, 2019
Cash Position: The Company had a total cash balance of CHF 302.5M, comprised of CHF 212.5M in cash and cash equivalents and CHF 90.0M in short-term financial assets. This compares to a total cash balance of CHF 186.5M as of December 31, 2018. The increase of CHF 116M is principally Because of the CHF 80M upfront payment, USD 50M convertible equity note, and CHF 30M milestone payment related to the contract with Lilly. The total shareholders’ equity position increased from December 31, 2018 to CHF 292.4M from CHF 177.6M. Further details are accessible in our corresponding Financial Statements filed on the accompanying Form 6-K
Revenues: Revenues for the three and nine months ended September 30, 2019 totaled CHF 33.4M and CHF 110M, respectively. This represents a raise of CHF 31.1M and CHF 104.2M contrast to the respective periods in 2018. The increase for the three-month period relates to the recognition of CHF 30.0M for the first installment of the first milestone achieved with Lilly and EUR 2M (CHF 2.2M) in connection with the initiation of a Phase 2 Trial of Tau PET Tracer with Life Molecular Imaging. The increase for the nine-month period is driven by the recognition of CHF 74.6M from the right-of-use license and research and development activities linked to the 2018 Lilly contract and a CHF 30M payment for the first installment of the first milestone achieved with Lilly
R&D Expenditures: R&D expenditures reduced by CHF 0.1M (-0.6%) and increased CHF 3.6M (+11%) for the three and nine months ended September 30, 2019 contrast to the comparable periods in 2018, respectively. The increase in R&D expenditures in 2019 was largely Because of increased investments in non-AD and new discovery programs. For non-AD, the Company increased investment in its Morphomer™ alpha-synuclein programs and continued to advance the clinical development of its anti-Abeta vaccine ACI-24 in Down Syndrome (DS). In new discovery, the Company continued to focus on its neuroinflammation discovery programs while also increasing investment in its anti-a-synuclein antibody. For AD, the Company’s expenditures for the anti-pTau vaccine program reduced Because of the completion of certain toxicology and manufacturing work in the previous year as well as a decrease for ACI-24 related to higher costs for the initiation of the Phase 2 study in the previous period
G&A Expenses: For the three and nine months ended September 30, 2019, G&A increased CHF 1.0M (+35%) and CHF 2.1M (+24%) to CHF 4.0M and CHF 10.8M, respectively. Increases are driven by rental, personnel and IT expenses
IFRS Income/(Loss) for the period: The Company recorded net income after taxes of CHF 18.2M and CHF 64.9M for the three and nine months ended September 30, 2019, respectively, contrast with net losses of CHF 13.5M and CHF 36.3M for the comparable periods in 2018.
AC Immune SA noticed change of 2.12% to $9.65 along volume of 62564 shares in recent session compared to an average volume of 140.85K. ACIU’s shares are at 85.58% for the quarter and driving a -10.90% return over the course of the past year and is now at 13.26% since this point in 2018. The average volatility for the week at 4.31% and for month was at 6.09%. There are 69.03M shares outstanding and 33.15M shares are floated in market. Right now the stock beta is 0.37.